Anti-TRAC/ IMD7/ TCRA monoclonal antibody
Anti-TRAC/ IMD7/ TCRA antibody for FACS & in-vivo assay
Go to TRAC/TRAC products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP1865-Ab-1/ GM-Tg-hg-MP1865-Ab-2 | Anti-Human TRAC monoclonal antibody | Human |
GM-Tg-rg-MP1865-Ab-1/ GM-Tg-rg-MP1865-Ab-2 | Anti-Rat TRAC monoclonal antibody | Rat |
GM-Tg-mg-MP1865-Ab-1/ GM-Tg-mg-MP1865-Ab-2 | Anti-Mouse TRAC monoclonal antibody | Mouse |
GM-Tg-cynog-MP1865-Ab-1/ GM-Tg-cynog-MP1865-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TRAC monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP1865-Ab-1/ GM-Tg-felg-MP1865-Ab-2 | Anti-Feline TRAC monoclonal antibody | Feline |
GM-Tg-cang-MP1865-Ab-1/ GM-Tg-cang-MP1865-Ab-2 | Anti-Canine TRAC monoclonal antibody | Canine |
GM-Tg-bovg-MP1865-Ab-1/ GM-Tg-bovg-MP1865-Ab-2 | Anti-Bovine TRAC monoclonal antibody | Bovine |
GM-Tg-equg-MP1865-Ab-1/ GM-Tg-equg-MP1865-Ab-2 | Anti-Equine TRAC monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP1865-Ab-1/ GM-Tg-hg-MP1865-Ab-2; GM-Tg-rg-MP1865-Ab-1/ GM-Tg-rg-MP1865-Ab-2; GM-Tg-mg-MP1865-Ab-1/ GM-Tg-mg-MP1865-Ab-2; GM-Tg-cynog-MP1865-Ab-1/ GM-Tg-cynog-MP1865-Ab-2; GM-Tg-felg-MP1865-Ab-1/ GM-Tg-felg-MP1865-Ab-2; GM-Tg-cang-MP1865-Ab-1/ GM-Tg-cang-MP1865-Ab-2; GM-Tg-bovg-MP1865-Ab-1/ GM-Tg-bovg-MP1865-Ab-2; GM-Tg-equg-MP1865-Ab-1/ GM-Tg-equg-MP1865-Ab-2 |
Products Name | Anti-TRAC monoclonal antibody |
Format | mab |
Target Name | TRAC |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-TRAC benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species TRAC/ IMD7/ TCRA VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP1865 |
Target Name | TRAC |
Gene ID | 28755 |
Gene Symbol and Synonyms | IMD7,TCRA,TRA,TRAC,TRCA |
Uniprot Accession | P01848 |
Uniprot Entry Name | TRAC_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000277734 |
Target Classification | N/A |
The target: TRAC, gene name: TRAC, also named as IMD7, TCRA, TRA, TRCA. T cell receptors recognize foreign antigens which have been processed as small peptides and bound to major histocompatibility complex (MHC) molecules at the surface of antigen presenting cells (APC). Each T cell receptor is a dimer consisting of one alpha and one beta chain or one delta and one gamma chain. In a single cell, the T cell receptor loci are rearranged and expressed in the order delta, gamma, beta, and alpha. If both delta and gamma rearrangements produce functional chains, the cell expresses delta and gamma. If not, the cell proceeds to rearrange the beta and alpha loci. This region represents the germline organization of the T cell receptor alpha and delta loci. Both the alpha and delta loci include V (variable), J (joining), and C (constant) segments and the delta locus also includes diversity (D) segments. The delta locus is situated within the alpha locus, between the alpha V and J segments. During T cell development, the delta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The alpha chain is synthesized by recombination joining a single V segment with a J segment. For both chains, the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. Five variable segments can be used in either alpha or delta chains and are described by TRAV/DV symbols. Several V and J segments of the alpha locus are known to be incapable of encoding a protein and are considered pseudogenes. [provided by RefSeq, Aug 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.